Viracta Therapeutics Announces Preliminary Dose-Ranging Data Of Nana-Val In Advanced Epstein-Barr Virus-Positive Solid Tumors

Viracta Therapeutics Inc VIRX:

• VIRACTA THERAPEUTICS ANNOUNCES PRELIMINARY DOSE-RANGING DATA FROM THE PHASE 1B/2 TRIAL OF NANA-VAL IN ADVANCED EPSTEIN-BARR VIRUS-POSITIVE (EBV+) SOLID TUMORS AT THE ESMO IMMUNO-ONCOLOGY CONGRESS

• COMPANY ANTICIPATES INITIATING PHASE 2 RANDOMIZED EXPANSION PORTION OF PHASE 1B/2 TRIAL IN SECOND HALF OF 2023

• COMPANY ANTICIPATES INITIATING PHASE 2 RANDOMIZED EXPANSION PORTION OF PHASE 1B/2 TRIAL IN SECOND HALF OF 2023

• NANA-VAL WAS WELL TOLERATED WITH NO DOSE LIMITING TOXICITIES (DLTS) REPORTED

• TWO OF SIX EVALUABLE PATIENTS ACHIEVED STABLE DISEASE (SD) PER RECIST V1.1 CRITERIA

• PLASMA EBV DNA TITERS DECREASED OR REMAINED STABLE IN BOTH PATIENTS ACHIEVING SD

• PLASMA EBV DNA TITERS ROSE IN PATIENTS WITH PROGRESSIVE DISEASE